Citations (82)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (9)
Nabeel Kajihara, Yoshino Tanaka, Riko Takeuchi, Takuto Kobayashi, Masafumi Tanji, Tsukasa Ataka, Shiho Nakano, Taisho Yamada, Akinori Takaoka, Yoshinori Hasegawa, Ken-Ichiro Seino & Haruka Wada. (2023) Augmented interferon regulatory factor 7 axis in whole tumor cell vaccines prevents tumor recurrence by inducing interferon gamma-secreting B cells. OncoImmunology 12:1.
Read now
Read now
Selvarajan Vanitha, Nidhi Chaubey, Siddhartha S. Ghosh & Pallab Sanpui. (2017) Recombinant human granulocyte macrophage colony stimulating factor (hGM-CSF): Possibility of nanoparticle-mediated delivery in cancer immunotherapy. Bioengineered 8:2, pages 120-123.
Read now
Read now
Alexandra Kirner, Andrea Mayer-Mokler & Carsten Reinhardt. (2014) IMA901: A multi-peptide cancer vaccine for treatment of renal cell cancer. Human Vaccines & Immunotherapeutics 10:11, pages 3179-3189.
Read now
Read now
Oliver Klein, Christopher Schmidt, Ashley Knights, Ian D Davis, Weisan Chen & Jonathan Cebon. (2011) Melanoma vaccines: developments over the past 10 years. Expert Review of Vaccines 10:6, pages 853-873.
Read now
Read now
Cara K Fraser, Michael P Brown, Kerrilyn R Diener & John D Hayball. (2010) Unravelling the complexity of cancer–immune system interplay. Expert Review of Anticancer Therapy 10:6, pages 917-934.
Read now
Read now
Luigi Aurisicchio & Gennaro Ciliberto. (2010) Patented cancer vaccines: the promising leads. Expert Opinion on Therapeutic Patents 20:5, pages 647-660.
Read now
Read now
Vincent G Brichard & Diane Lejeune. (2008) Cancer immunotherapy targeting tumour-specific antigens: towards a new therapy for minimal residual disease. Expert Opinion on Biological Therapy 8:7, pages 951-968.
Read now
Read now
Leisha A Emens. (2008) Cancer vaccines: on the threshold of success. Expert Opinion on Emerging Drugs 13:2, pages 295-308.
Read now
Read now
James E Ward & Douglas G McNeel. (2007) GVAX: an allogeneic, whole-cell, GM-CSF-secreting cellular immunotherapy for the treatment of prostate cancer. Expert Opinion on Biological Therapy 7:12, pages 1893-1902.
Read now
Read now
Articles from other publishers (73)
Eddie Grimmett, Bayan Al-Share, Mohamad Basem Alkassab, Ryan Weng Zhou, Advait Desai, Mir Munir A. Rahim & Indryas Woldie. (2022) Cancer vaccines: past, present and future; a review article. Discover Oncology 13:1.
Crossref
Crossref
Navami Prabhakar Koyande, Rupali Srivastava, Ananya Padmakumar & Aravind Kumar Rengan. (2022) Advances in Nanotechnology for Cancer Immunoprevention and Immunotherapy: A Review. Vaccines 10:10, pages 1727.
Crossref
Crossref
Mahnaz Rezaei, Natalia D. Danilova, Mojdeh Soltani, Lyudmila V. Savvateeva, Vadim V. Tarasov, Mazdak Ganjalikhani-Hakemi, Alexandr V. Bazhin & Andrey A. Zamyatnin. (2022) Cancer Vaccine in Cold Tumors: Clinical Landscape, Challenges, and
Opportunities. Current Cancer Drug Targets 22:6, pages 437-453.
Crossref
Crossref
Jin-Qing Liu, Chengxiang Zhang, Xinfu Zhang, Jingyue Yan, Chunxi Zeng, Fatemeh Talebian, Kimberly Lynch, Weiyu Zhao, Xucheng Hou, Shi Du, Diana D. Kang, Binbin Deng, David W. McComb, Xue-Feng Bai & Yizhou Dong. (2022) Intratumoral delivery of IL-12 and IL-27 mRNA using lipid nanoparticles for cancer immunotherapy. Journal of Controlled Release 345, pages 306-313.
Crossref
Crossref
Somnath Roy, Joydeep Ghosh & Ranti Ghosh. (2021) Cancer Vaccine in Solid Tumors: Where We Stand. Indian Journal of Medical and Paediatric Oncology 42:04, pages 319-324.
Crossref
Crossref
Mina Shahnazari, Pouria Samadi, Mona Pourjafar & Akram Jalali. (2020) Therapeutic vaccines for colorectal cancer: The progress and future prospect. International Immunopharmacology 88, pages 106944.
Crossref
Crossref
Sohini Roy, Tarsheen K. Sethi, David Taylor, Young J. Kim & Douglas B. Johnson. (2020) Breakthrough concepts in immune‐oncology: Cancer vaccines at the bedside. Journal of Leukocyte Biology 108:4, pages 1455-1489.
Crossref
Crossref
Hong Sung Kim. (2019) Development of Genetically Modified Tumor Cell Containing Co-stimulatory Molecule. Biomedical Science Letters 25:4, pages 398-406.
Crossref
Crossref
Robert E. Hollingsworth & Kathrin Jansen. (2019) Turning the corner on therapeutic cancer vaccines. npj Vaccines 4:1.
Crossref
Crossref
Nusrat Jahan, Hammad Talat & William T Curry. (2018) Agonist OX40 immunotherapy improves survival in glioma-bearing mice and is complementary with vaccination with irradiated GM-CSF–expressing tumor cells. Neuro-Oncology 20:1, pages 44-54.
Crossref
Crossref
Lisa H. Butterfield, Fengmin Zhao, Sandra Lee, Ahmad A. Tarhini, Kim A. Margolin, Richard L. White, Michael B. Atkins, Gary I. Cohen, Theresa L. Whiteside, John M. Kirkwood & David H. Lawson. (2017) Immune Correlates of GM-CSF and Melanoma Peptide Vaccination in a Randomized Trial for the Adjuvant Therapy of Resected High-Risk Melanoma (E4697). Clinical Cancer Research 23:17, pages 5034-5043.
Crossref
Crossref
C Sakamoto, H Kohara, H Inoue, M Narusawa, Y Ogawa, L Hirose-Yotsuya, S Miyamoto, Y Matsumura, K Yamada, A Takahashi & K Tani. (2017) Therapeutic vaccination based on side population cells transduced by the granulocyte–macrophage colony-stimulating factor gene elicits potent antitumor immunity. Cancer Gene Therapy 24:4, pages 165-174.
Crossref
Crossref
Lies A.L. Fliervoet & Enrico Mastrobattista. (2016) Drug delivery with living cells. Advanced Drug Delivery Reviews 106, pages 63-72.
Crossref
Crossref
Roy Rampling, Sharon Peoples, Paul J. Mulholland, Allan James, Omar Al-Salihi, Christopher J. Twelves, Catherine McBain, Sarah Jefferies, Alan Jackson, Willie Stewart, Juha Lindner, Sarah Kutscher, Norbert Hilf, Lesley McGuigan, Jane Peters, Karen Hill, Oliver Schoor, Harpreet Singh-Jasuja, Sarah E. Halford & James W.A. Ritchie. (2016) A Cancer Research UK First Time in Human Phase I Trial of IMA950 (Novel Multipeptide Therapeutic Vaccine) in Patients with Newly Diagnosed Glioblastoma. Clinical Cancer Research 22:19, pages 4776-4785.
Crossref
Crossref
Manzoor M KhanManzoor M. Khan. 2016. Immunopharmacology. Immunopharmacology
363
396
.
Steven J Conrad, Mohamed El-Aswad, Esaw Kurban, David Jeng, Brian C Tripp, Charles Nutting, Robert Eversole, Charles Mackenzie & Karim Essani. (2015) Oncolytic tanapoxvirus expressing FliC causes regression of human colorectal cancer xenografts in nude mice. Journal of Experimental & Clinical Cancer Research 34:1.
Crossref
Crossref
Pramod K. Srivastava. (2015) Neoepitopes of Cancers: Looking Back, Looking Ahead. Cancer Immunology Research 3:9, pages 969-977.
Crossref
Crossref
S Detchokul, E D Williams, M W Parker & A G Frauman. (2014) Tetraspanins as regulators of the tumour microenvironment: implications for metastasis and therapeutic strategies. British Journal of Pharmacology 171:24, pages 5462-5490.
Crossref
Crossref
Sandra Demaria, Karsten A. Pilones, Claire Vanpouille-Box, Encouse B. Golden & Silvia C. Formenti. (2014) The Optimal Partnership of Radiation and Immunotherapy: from Preclinical Studies to Clinical Translation. Radiation Research 182:2, pages 170-181.
Crossref
Crossref
Peter Working. 2014. The Role of the Study Director in Nonclinical Studies. The Role of the Study Director in Nonclinical Studies
427
437
.
Georg F. Weber, Benjamin G. Chousterman, Ingo Hilgendorf, Clinton S. Robbins, Igor Theurl, Louisa M.S. Gerhardt, Yoshiko Iwamoto, Tam D. Quach, Muhammad Ali, John W. Chen, Thomas L. Rothstein, Matthias Nahrendorf, Ralph Weissleder & Filip K. Swirski. (2014) Pleural innate response activator B cells protect against pneumonia via a GM-CSF-IgM axis. Journal of Experimental Medicine 211:6, pages 1243-1256.
Crossref
Crossref
Meaghan L Khan, Thorvardur R Halfdanarson & Mitesh J Borad. (2014) Immunotherapeutic and oncolytic viral therapeutic strategies in pancreatic cancer. Future Oncology 10:7, pages 1255-1275.
Crossref
Crossref
Jurjen M Ruben, Lindy L Visser, Hetty J Bontkes, Theresia M Westers, Gert J Ossenkoppele, Tanja D de Gruijl & Arjan A van de Loosdrecht. (2013) Targeting the acute myeloid leukemic stem cell compartment by enhancing tumor cell-based vaccines. Immunotherapy 5:8, pages 859-868.
Crossref
Crossref
Spencer C. Liang, Marina Moskalenko, Melinda Van Roey & Karin Jooss. (2013) Depletion of regulatory T cells by targeting folate receptor 4 enhances the potency of a GM-CSF-secreting tumor cell immunotherapy. Clinical Immunology 148:2, pages 287-298.
Crossref
Crossref
Elena Niccolai, Domenico Prisco, Mario Milco D'Elios & Amedeo Amedei. (2013) What Is Recent in Pancreatic Cancer Immunotherapy?. BioMed Research International 2013, pages 1-14.
Crossref
Crossref
Kevin C. Soares, Lei Zheng, Barish Edil & Elizabeth M. Jaffee. (2012) Vaccines for Pancreatic Cancer. The Cancer Journal 18:6, pages 642-652.
Crossref
Crossref
Gerrit Koopman, Niels Beenhakker, Sam Hofman, Lilian Walther-Jallow, Barbro M?kitalo, Petra Mooij, Jan Anderson, Ernst Verschoor, Willy M.J. Bogers, Jonathan L. Heeney & Anna-Lena Spetz. (2012) Immunization with apoptotic pseudovirus transduced cells induces both cellular and humoral responses: A proof of concept study in macaques. Vaccine 30:15, pages 2523-2534.
Crossref
Crossref
Vivian L. Weiss, Timothy H. Lee, Hong Song, Theodore S. Kouo, Chelsea M. Black, George Sgouros, Elizabeth M. Jaffee & Todd D. Armstrong. (2012) Trafficking of High Avidity HER-2/neu-Specific T Cells into HER-2/neu-Expressing Tumors after Depletion of Effector/Memory-Like Regulatory T Cells. PLoS ONE 7:2, pages e31962.
Crossref
Crossref
David A. Zaharoff, Michael Heffernan, Jonathan Fallon & John W. Greiner. 2012. Chitosan‐Based Systems for Biopharmaceuticals. Chitosan‐Based Systems for Biopharmaceuticals
525
541
.
Brian W. C. Tse, Kieran F. Scott & Pamela J. Russell. (2012) Paradoxical Roles of Tumour Necrosis Factor-Alpha in Prostate Cancer Biology. Prostate Cancer 2012, pages 1-8.
Crossref
Crossref
Thomas S. Griffith & Thomas A. Ferguson. (2011) Cell Death in the Maintenance and Abrogation of Tolerance: The Five Ws of Dying Cells. Immunity 35:4, pages 456-466.
Crossref
Crossref
Luigi Aurisicchio & Gennaro Ciliberto. (2011) Emerging Cancer Vaccines: The Promise of Genetic Vectors. Cancers 3:3, pages 3687-3713.
Crossref
Crossref
Marcio O Lasaro, Marina Sazanovich, Wynetta Giles-Davis, Paulus Mrass, Ralph M Bunte, Duane A Sewell, S Farzana Hussain, Yang-Xin Fu, Wolfgang Weninger, Yvonne Paterson & Hildegund CJ Ertl. (2011) Active Immunotherapy Combined With Blockade of a Coinhibitory Pathway Achieves Regression of Large Tumor Masses in Cancer-prone Mice. Molecular Therapy 19:9, pages 1727-1736.
Crossref
Crossref
Glenda Canderan, Peter Wilkinson, John Schatzle, Mark Cameron & Rafick-Pierre Sekaly. 2011. Cancer Vaccines. Cancer Vaccines
167
181
.
Glenda Canderan, Peter Wilkinson, John Schatzle, Mark Cameron & Rafick-Pierre Sekaly. 2011. Cancer Vaccines: From Research to Clinical Practice. Cancer Vaccines: From Research to Clinical Practice
167
181
.
J Westermann, A Flörcken, G Willimsky, A van Lessen, J Kopp, A Takvorian, K Jöhrens, A Lukowsky, C Schönemann, B Sawitzki, H Pohla, R Frank, B Dörken, D J Schendel, T Blankenstein & A Pezzutto. (2010) Allogeneic gene-modified tumor cells (RCC-26/IL-7/CD80) as a vaccine in patients with metastatic renal cell cancer: a clinical phase-I study. Gene Therapy 18:4, pages 354-363.
Crossref
Crossref
Sujitra Detchokul & Albert G. Frauman. (2011) Recent developments in prostate cancer biomarker research: therapeutic implications. British Journal of Clinical Pharmacology 71:2, pages 157-174.
Crossref
Crossref
Shigeo Koido, Sadamu Homma, Akitaka Takahara, Yoshihisa Namiki, Shintaro Tsukinaga, Jimi Mitobe, Shunichi Odahara, Toyokazu Yukawa, Hiroshi Matsudaira, Keisuke Nagatsuma, Kan Uchiyama, Kenichi Satoh, Masaki Ito, Hideo Komita, Hiroshi Arakawa, Toshifumi Ohkusa, Jianlin Gong & Hisao Tajiri. (2011) Current Immunotherapeutic Approaches in Pancreatic Cancer. Clinical and Developmental Immunology 2011, pages 1-15.
Crossref
Crossref
Robert D. Loberg & Kenneth J. Pienta. 2010. Bone Cancer. Bone Cancer
441
448
.
John P. Neoptolemos, Raul Urrutia, James L. Abbruzzese & Markus W. BüchlerLei Zheng & Elizabeth M. Jaffee. 2010. Pancreatic Cancer. Pancreatic Cancer
1269
1318
.
Betty Li, Andrew Simmons, Thomas Du, Carol Lin, Marina Moskalenko, Melissa Gonzalez-Edick, Melinda VanRoey & Karin Jooss. (2009) Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies. Clinical Immunology 133:2, pages 184-197.
Crossref
Crossref
Ivan M. BorrelloHyam I. LevitskyWendy StockDorie SherLu QinDaniel J. DeAngeloEdwin P. AlyeaRichard M. StoneLloyd E. Damon, Charles A. Linker, Daniel J. Maslyar & Kristen M. Hege. (2009) Granulocyte-macrophage colony-stimulating factor (GM-CSF)–secreting cellular immunotherapy in combination with autologous stem cell transplantation (ASCT) as postremission therapy for acute myeloid leukemia (AML). Blood 114:9, pages 1736-1745.
Crossref
Crossref
Kazuhiro Kakimi, Jun Nakajima & Hiromi Wada. (2009) Active specific immunotherapy and cell-transfer therapy for the treatment of non-small cell lung cancer. Lung Cancer 65:1, pages 1-8.
Crossref
Crossref
Shin-ichiro Fujii, Takuya Takayama, Miki Asakura, Kaori Aki, Koji Fujimoto & Kanako Shimizu. (2009) Dendritic cell-based cancer immunotherapies. Archivum Immunologiae et Therapiae Experimentalis 57:3, pages 189-198.
Crossref
Crossref
Matthew R. Buckwalter & Matthew L. Albert. (2009) Orchestration of the immune response by dendritic cells. Current Biology 19:9, pages R355-R361.
Crossref
Crossref
Gregory Driessens, Paul Hoffmann, Michael Pouwels, Alexandre Zlotta, Claude Schulman, Thierry Velu & Catherine A. Bruyns. (2009) Synergy Between Dendritic Cells and GM–CSF-secreting Tumor Cells for the Treatment of a Murine Renal Cell Carcinoma. Journal of Immunotherapy 32:2, pages 140-144.
Crossref
Crossref
D Hoang-Le, L Smeenk, I Anraku, G P Pijlman, X J Wang, J de Vrij, W J Liu, T T Le, W A Schroder, A A Khromykh & A Suhrbier. (2008) A Kunjin replicon vector encoding granulocyte macrophage colony-stimulating factor for intra-tumoral gene therapy. Gene Therapy 16:2, pages 190-199.
Crossref
Crossref
Karin Enell Smith, Sara Fritzell, Wiaam Badn, Sofia Eberstål, Shorena Janelidze, Edward Visse, Anna Darabi & Peter Siesjö. (2008)
Cure of established GL261 mouse gliomas after combined immunotherapy with GM‐CSF and IFNγ is mediated by both CD8
+
and CD4
+
T‐cells
. International Journal of Cancer 124:3, pages 630-637.
Crossref
Crossref
Shigeo Koido, Eiichi Hara, Sadamu Homma, Yoshihisa Namiki, Toshifumi Ohkusa, Jianlin Gong & Hisao Tajiri. (2009) Cancer Vaccine by Fusions of Dendritic and Cancer Cells. Clinical and Developmental Immunology 2009, pages 1-13.
Crossref
Crossref
N Lei, F B Shen, J H Chang, L Wang, H Li, C Yang, J Li & D C Yu. (2008) An oncolytic adenovirus expressing granulocyte macrophage colony-stimulating factor shows improved specificity and efficacy for treating human solid tumors. Cancer Gene Therapy 16:1, pages 33-43.
Crossref
Crossref
Jinhua Li, Ada V. King, Sara L. Stickel, Kelly E. Burgin, Xinhai Zhang, Thomas E. Wagner & Yanzhang Wei. (2009) Whole tumor cell vaccine with irradiated S180 cells as adjuvant. Vaccine 27:4, pages 558-564.
Crossref
Crossref
Kenneth B. DeSantes & Paul M. Sondel. 2009. Oncology of Infancy and Childhood. Oncology of Infancy and Childhood
209
240
.
Jian Qiao & Haidong Dong. 2009. Targeted Cancer Immune Therapy. Targeted Cancer Immune Therapy
117
131
.
Hiroyuki Inoue, Mutsunori Iga, Haruka Nabeta, Tomoko Yokoo, Yoko Suehiro, Shinji Okano, Makoto Inoue, Hiroaki Kinoh, Toyomasa Katagiri, Koichi Takayama, Yoshikazu Yonemitsu, Mamoru Hasegawa, Yusuke Nakamura, Yoichi Nakanishi & Kenzaburo Tani. (2008) Non-transmissible Sendai virus encoding granulocyte macrophage colony-stimulating factor is a novel and potent vector system for producing autologous tumor vaccines. Cancer Science 99:11, pages 2315-2326.
Crossref
Crossref
Heidi V. Russell, Douglas Strother, Zhuyong Mei, Donna Rill, Edwina Popek, Ettore Biagi, Eric Yvon, Malcolm Brenner & Raphael Rousseau. (2008) A Phase 1/2 Study of Autologous Neuroblastoma Tumor Cells Genetically Modified to Secrete IL-2 in Patients With High-risk Neuroblastoma. Journal of Immunotherapy 31:9, pages 812-819.
Crossref
Crossref
Tanja D. de Gruijl, Alfons J. M. van den Eertwegh, Herbert M. Pinedo & Rik J. Scheper. (2008) Whole-cell cancer vaccination: from autologous to allogeneic tumor- and dendritic cell-based vaccines. Cancer Immunology, Immunotherapy 57:10, pages 1569-1577.
Crossref
Crossref
Hiroyuki Inoue, Mutsunori Iga, Meng Xin, Saori Asahi, Takafumi Nakamura, Ryo Kurita, Masaharu Nakayama, Yukoh Nakazaki, Koichi Takayama, Yoichi Nakanishi & Kenzaburo Tani. (2008) TARC and RANTES enhance antitumor immunity induced by the GM-CSF-transduced tumor vaccine in a mouse tumor model. Cancer Immunology, Immunotherapy 57:9, pages 1399-1411.
Crossref
Crossref
Betty Li, Melinda VanRoey, Frederic Triebel & Karin Jooss. (2008) Lymphocyte Activation Gene-3 Fusion Protein Increases the Potency of a Granulocyte Macrophage Colony-Stimulating Factor–Secreting Tumor Cell Immunotherapy. Clinical Cancer Research 14:11, pages 3545-3554.
Crossref
Crossref
Arthur W. Nienhuis. (2008) Development of gene therapy for blood disorders. Blood 111:9, pages 4431-4444.
Crossref
Crossref
Jian-Qing Gao, Naoki Okada, Tadanori Mayumi & Shinsaku Nakagawa. (2007) Immune Cell Recruitment and Cell-Based System for Cancer Therapy. Pharmaceutical Research 25:4, pages 752-768.
Crossref
Crossref
Marcella Fassò, Rebecca Waitz, Yafei HouTae Rim, Norman M. Greenberg, Nilabh ShastriLawrence FongJames P. Allison. (2008) SPAS-1 (stimulator of prostatic adenocarcinoma-specific T cells)/SH3GLB2: A prostate tumor antigen identified by CTLA-4 blockade. Proceedings of the National Academy of Sciences 105:9, pages 3509-3514.
Crossref
Crossref
Roopa Srinivasan. 2008. Cancer Vaccines: Challenges and Opportunities in Translation. Cancer Vaccines: Challenges and Opportunities in Translation
55
68
.
Pedro Romero. (2008) Current State of Vaccine Therapies in Non–Small-Cell Lung Cancer. Clinical Lung Cancer 9, pages S28-S36.
Crossref
Crossref
Hee-Young KimGil-Soon ParkHo-Joon ShinSun ParkKyongmin KimHyung-Il Kim. (2008) Secretion of Biologically Active Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor by Transduced Gastric Cancer Cells. Yonsei Medical Journal 49:2, pages 279.
Crossref
Crossref
Stanimir Vuk-Pavlovic. (2008) Rebuilding immunity in cancer patients. Blood Cells, Molecules, and Diseases 40:1, pages 94-100.
Crossref
Crossref
Annelie Vulink, Kristen J. Radford, Cornelis Melief & Derek N.J. Hart. 2008.
363
407
.
Manzoor M. KhanManzoor M. Khan. 2008. Immunopharmacology. Immunopharmacology
227
252
.
Jürgen Scherer, Thomas Hinz & Klaus Cichutek. (2007) Trends in der Impfstoffentwicklung. DNA‐ und zellbasierte Impfstoffe. Pharmazie in unserer Zeit 37:1, pages 86-92.
Crossref
Crossref
John Stagg, Ricky W. Johnstone & Mark J. Smyth. (2007) From cancer immunosurveillance to cancer immunotherapy. Immunological Reviews 220:1, pages 82-101.
Crossref
Crossref
David A. Zaharoff, Connie J. Rogers, Kenneth W. Hance, Jeffrey Schlom & John W. Greiner. (2007) Chitosan solution enhances the immunoadjuvant properties of GM-CSF. Vaccine 25:52, pages 8673-8686.
Crossref
Crossref
Lilah F. Morris & Antoni Ribas. (2007) Therapeutic Cancer Vaccines. Surgical Oncology Clinics of North America 16:4, pages 819-831.
Crossref
Crossref
Russel S. Taichman, Robert D. Loberg, Rohit Mehra & Kenneth J. Pienta. (2007) The evolving biology and treatment of prostate cancer. Journal of Clinical Investigation 117:9, pages 2351-2361.
Crossref
Crossref
Erika A. Eksioglu, Syed S. Mahmood, Myron Chang & Vijay Reddy. (2007) GM-CSF promotes differentiation of human dendritic cells and T lymphocytes toward a predominantly type 1 proinflammatory response. Experimental Hematology 35:8, pages 1163-1171.
Crossref
Crossref